Navigation Links
Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests
Date:12/11/2008

REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, December 11 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), a leading developer of microRNA-based molecular diagnostics, announced today the commercial availability of its first diagnostic test, miRview(TM) squamous. The test is now commercially available through Rosetta Genomics CLIA-certified lab in Philadelphia.

To order the test, physicians may contact 1-888-522-7971, or visit the company's website http://www.rosettagenomics.com.

"The introduction of miRview(TM) squamous, our first microRNA-based test, is a landmark event for us at Rosetta Genomics," said Amir Avniel, President and CEO of Rosetta Genomics. "We are excited to be offering the first objective diagnostic test for differentiation of NSCLC patients, which is based on our proprietary microRNA technology. miRview(TM) squamous offers physicians a standardized, quantitative diagnostic tool which may assist in determining the appropriate targeted therapy for NSCLC."

The test has a reported sensitivity of 97%, and a specificity of 91% in identifying squamous cell lung cancer. Classification accuracy was measured in a blinded test of a validation set of 64 samples, compared to the consensus diagnosis of at least two pathologists.

In blinded tests of lab-to-lab concordance, two labs reached the same classification in >95% of classified samples.

"We have traveled a significant distance from first discovering microRNA sequences, through the development of our proprietary detection and quantification technologies, to having our first commercially available microRNA-based test," noted Dr. Dalia Cohen, Rosetta Genomics Chief Scientific Office." miRview(TM) squamous is designed to offer a quantitative, objective, and standardized diagnostic tool for differentiating squamous from non
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Columbia University Medical Center and Rosetta Genomics Announce Columbia Universitys Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica
2. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
3. Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
4. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
5. Rosetta Genomics and Rabin Medical Center Announce a Collaboration Focused on MicroRNA-Based Diagnostics
6. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
7. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
8. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
9. Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum
10. MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma
11. Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics miRview(TM) Squamous Assay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... CHENGDU, China , Jan. 23, 2015 Tianyin ... pharmaceutical company that specializes in the development and sale ... branded generics and active pharmaceutical ingredients (API) today announced ... Facility (JCM) API operation. 1. Following the ...
(Date:1/22/2015)... 2015  ResMed Inc. (NYSE: RMD ) today announced ... the quarter was $423.0 million, a 10 percent increase compared ... increase on a constant currency basis). Net income was $91.2 ... ended December 31, 2013. Diluted earnings per share for the ...
(Date:1/22/2015)... 22, 2015  Profil Institute for Clinical Research, Inc., a ... announced today a new textbook,  Translational Research Methods for ... a leading global scientific publisher. The textbook ... for use in early phase clinical studies of new ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
... 4, 2011 Adherence to strict outcome requirements ... Services (CMS) has an adverse effect on liver ... than optimal conditions, according to researchers at Northwestern ... quality improvement initiatives aim to enhance post-transplant outcomes, ...
... OAKS, Calif. and NEW YORK, Nov. 5, 2011 Amgen ... PFE ) today announced results of the second and ... multi-center trial in patients with moderately active rheumatoid arthritis (RA) ... (LDA) or clinical remission on combination Enbrel® (etanercept) plus methotrexate ...
Cached Medicine Technology:Study Calls for Modification of CMS Conditions of Participation to Preserve Access to Life-Saving Liver Transplantations under Less than Optimal Conditions 2Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 2Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 3Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 4Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 5Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 6Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 7Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 8Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 9Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 10Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease 11
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... January 22, 2015 Four years since the release ... which coincided with the marriage of Avasa & Matthew Love – ... which is scheduled for release through White Swan Records on February ... there is a sacred path available to all of us to ...
(Date:1/22/2015)... a famous dress online store for wedding dresses and other ... of wedding dresses , and launches a site-wide women’s dress ... on your big day; the wedding gown is the most ... find the most suitable wedding dress. Now, we are proud ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... NASHVILLE, Tenn., Nov. 10 Healthcare Realty,Trust Incorporated (NYSE: ... quarter,ended September 30, 2008. Funds from operations ("FFO") per ... same period in 2007. FFO,per diluted common share totaled ... with the prior year,s $1.13. FFO would have been ...
... patients or women who want to delay childbirth , , ... the ability to freeze and transplant ovaries, a development ... therapy. , "We can transplant ovaries without any loss ... normally whether it,s fresh or frozen," said co-researcher Dr. ...
... Omega Protein Corporation,(NYSE: OME ), the nation,s ... products, today reported net income of $3.1 million (17,cents ... to net income of,$7.2 million (42 cents a share) ... (Logo: http://www.newscom.com/cgi-bin/prnh/20030516/OMEGALOGO ), Revenues for the third ...
... Inc. ( www.infotrieve.com ), the global leader in business service solutions ... Content SCM software solution at the biopharma company UCB, headquartered in ... ... EON) November 10, 2008 -- Content SCM is Infotrieve,s revolutionary ...
... Thermage, Inc.,(Nasdaq: THRM ), a leader in ... results for the third quarter ended,September 30, 2008. Reliant ... quarter., Thermage revenue for the third quarter of ... million for the third quarter of 2007. Domestic,revenue decreased ...
... LAKE FOREST, Ill., Nov. 10 Hospira, Inc.,(NYSE: ... medication delivery,company, announced today that Ken Meyers has ... Development. In this,capacity, he will lead the global ... high-performance culture and organizational excellence.,Meyers succeeds Henry Weishaar, ...
Cached Medicine News:Health News:Healthcare Realty Trust Announces Third Quarter Results 2Health News:Healthcare Realty Trust Announces Third Quarter Results 3Health News:Healthcare Realty Trust Announces Third Quarter Results 4Health News:Healthcare Realty Trust Announces Third Quarter Results 5Health News:Healthcare Realty Trust Announces Third Quarter Results 6Health News:Healthcare Realty Trust Announces Third Quarter Results 7Health News:Healthcare Realty Trust Announces Third Quarter Results 8Health News:Healthcare Realty Trust Announces Third Quarter Results 9Health News:Freezing Ovaries Preserves Fertility, Scientists Report 2Health News:Freezing Ovaries Preserves Fertility, Scientists Report 3Health News:Omega Protein Reports 17 Cents Per Share Third Quarter Profit 2Health News:Omega Protein Reports 17 Cents Per Share Third Quarter Profit 3Health News:Omega Protein Reports 17 Cents Per Share Third Quarter Profit 4Health News:Omega Protein Reports 17 Cents Per Share Third Quarter Profit 5Health News: Infotrieve's Revolutionary Content SCM Solution Launched at UCB 2Health News: Infotrieve's Revolutionary Content SCM Solution Launched at UCB 3Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 2Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 3Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 4Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 5Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 6Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 7Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 8Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 9Health News:Hospira Names Ken Meyers to Lead Human Resources 2
... fixation with the Pennig Minifixator, combines the advantage ... procedure. Soft tissue dissection is not necessary, since ... now, external fixation in the hand has required ... of cases (Asche and Burny) because of the ...
The Medium External Fixator has a double-rod frame, medium Combination Clamp medium Multi-Pin Clamp, and Carbon Fiber Rods. Rod Attachment for Medium Multi-Pin Clamp allows second rod to be added....
... a low osmolar ionic dimer. Each ... meglumine, 196 mg of ioxaglate sodium ... disodium as a stabilizer. The solution ... each milliliter and provides 32% (320 ...
... IMAGOPAQUE is a non-ionic monomeric contrast ... in adults and children. After a decade ... 3.5 million examinations, IMAGOPAQUE has proven to ... effort in hundreds of radiology departments.Results from ...
Medicine Products: